NDA 50705/S-018

SUPPLEMENT APPROVAL

sanofi-aventis U.S. LLC
c/o Sanofi US Services, Inc.
Attention: Ying Zheng, PhD
Senior Associate, Regulatory Affairs
55 Corporate Drive, Mail Stop: 55C-205A
Bridgewater, NJ 08807

Dear Dr. Zheng:

Please refer to your supplemental new drug application (sNDA) dated December 12, 2019, received December 12, 2019, and your amendment, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for RIFATER (rifampin, isoniazid, pyrazinamide USP) Tablets, 120 mg/50 mg/300 mg.

This Prior Approval supplemental new drug application provides for a response to the Agency supplement request letter dated November 12, 2019, that recommended modifying the language in the package insert referring to RIFATER as a combination product and to its individual components throughout the **BOXED WARNING**, **CONTRAINDICATIONS**, **WARNINGS,** and **PRECAUTIONS** sections. Additionally, the following changes have been made to the labeling:

- Under **PRECAUTIONS,** updates to the package insert to address concomitant administration of RIFATER with drugs metabolized by certain cytochrome P-450 enzymes as RIFATER contains both inducer (rifampin) and inhibitor (isoniazid) of these enzymes.
- Under **OVERDOSAGE**, updates to human experience with individual components of RIFATER.

Additionally, minor editorial revisions have been made throughout the package insert.

APPROVAL & LABELING

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.[1] Content of labeling must be identical to the enclosed labeling (text for the package insert), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.[2]

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Mr. Gregory DiBernardo, Regulatory Project Manager, at (301) 796-4063.

Sincerely,

{See appended electronic signature page}

Dmitri Iarikov, MD, PhD
Deputy Director
Division of Anti-Infectives
Office of Infectious Diseases
Center for Drug Evaluation and Research

ENCLOSURE:

- Content of Labeling
    - Package Insert

[1] http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm
[2] We update guidances periodically. For he most recent version of a guidance, check the FDA Guidance Documents Database https://www.fda.gov/RegulatoryInformation/Guidances/default.htm.

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

DMITRI IARIKOV
05/12/2020 09:43:41 AM